SOURCE: BIOLASE Technology, Inc.

BIOLASE Technology, Inc.

September 27, 2010 08:00 ET

BIOLASE Announces Definitive Non-Exclusive Distribution Agreement With Henry Schein

BIOLASE to Sell Entire Product Line on a Multi-Distributor and Direct Basis

IRVINE, CA--(Marketwire - September 27, 2010) - BIOLASE Technology, Inc. (NASDAQ: BLTI), the world's leading dental laser company, announced today that BIOLASE and Henry Schein, Inc. (NASDAQ: HSIC) have entered into a definitive agreement, by which Henry Schein will change its relationship with BIOLASE into a non-exclusive distributor of BIOLASE dental laser systems and consumables in North America. This constitutes a significant change because Henry Schein was BIOLASE's exclusive North American distributor from August 2006 through August 2010. 

BIOLASE will sell through other North American distributors and will sell on a direct basis through its existing and currently expanding 22 person sales force. Henry Schein will retain exclusivity in certain, well-performing, international markets and remain non-exclusive in others. The distribution agreement is effective as of August 30, 2010. 

Federico Pignatelli, BIOLASE's Chairman and CEO, commented, "Henry Schein and BIOLASE have enjoyed a long-standing, working relationship over the last few years. We will continue collaborating in a constructive way to further the penetration of lasers into the dental market. I am pleased to announce this change in BIOLASE's business model, as it now allows our Company to leverage the full dental marketplace. Our patented Waterlase® YSGG technology for hard tissue and our soft-tissue diode product lines are unparalleled in the dental industry."

BIOLASE has sold and installed over 14,000 dental lasers worldwide, and is by a wide margin the market leader in the field of laser dentistry.

About BIOLASE Technology, Inc.
BIOLASE Technology, Inc., the world's leading dental laser company, is a medical technology company that develops, manufactures and markets lasers and related products focused on technologies that advance the practice of dentistry and medicine. The Company's products incorporate patented and patent pending technologies designed to provide clinically superior performance with less pain and faster recovery times. BIOLASE's principal products are dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications. Other products under development address ophthalmology and other medical and consumer markets.

For updates and information on laser and Waterlase dentistry, find BIOLASE at, Twitter at, and YouTube at

This press release may contain forward-looking statements within the meaning of safe harbor provided by the Securities Reform Act of 1995 that are based on the current expectations and estimates by our management. These forward-looking statements can be identified through the use of words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "may," "will," and variations of these words or similar expressions. Forward-looking statements are based on management's current, preliminary expectations and are subject to risks, uncertainties and other factors which may cause the Company's actual results to differ materially from the statements contained herein, and are described in the Company's reports it files with the Securities and Exchange Commission, including its annual and quarterly reports. No undue reliance should be placed on forward-looking statements. Such information is subject to change, and we undertake no obligation to update such statements.

Contact Information

  • For further information, please contact:
    Jill Bertotti (investors)
    Len Hall (media)
    Allen & Caron